Preliminary Safety, Efficacy, and Cellular Kinetics of CTA313, a CD19/BCMA Dual-Targeted Universal CAR-T Therapy, for Active Systemic Lupus Erythematosus
Release Time:
2025-09-28
Source:
Bioheng
Reprint to:
null
Presentation
Contact Us